Related Content
- Court rules in favor of Watson in generic Fentora patent suit
- Merck's hepatitis C drug granted priority review by FDA
- GPhA responds to potential OGD funding cuts; announces exit of Gordon Johnston
- Sandoz announces FDA approval, U.S. launch of chemotherapy drug
- FDA releases annual 'Generic Drug Roundup'
PARSIPPANY, N.J. — A court has ruled that patents covering a drug designed to treat an overactive bladder are invalid, a company looking to launch a generic version of the drug said.
Watson Pharmaceuticals said the U.S. District Court for the District of Delaware ruled that five patents covering Allergan's Sanctura XR (trospium chloride) extended-release capsules were invalid. Watson's application with the Food and Drug Administration for a generic version are pending, the company said.
Sanctura XR had sales of $68 million during the 12-month period ended in February, according to IMS Health.
Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.
